Ornithine decarboxylase activity in prostate cancer

О А Samoylenko1, E O Stakhovsky2, Y V Vitruk2

  • 1R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology NAS of Ukraine, Kyiv 03022, Ukraine.

Experimental Oncology
|March 31, 2021
PubMed
Summary

Ornithine decarboxylase activity (AODC) may serve as an auxiliary biomarker for prostate cancer (PCa) diagnosis. Elevated AODC correlates with higher Gleason scores and advanced clinical stages in PCa patients.